Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.15
EW's Cash to Debt is ranked higher than
59% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. EW: 1.15 )
EW' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 1.15

Equity to Asset 0.51
EW's Equity to Asset is ranked higher than
56% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. EW: 0.51 )
EW' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.74
Current: 0.51

0.37
0.74
Interest Coverage 46.38
EW's Interest Coverage is ranked higher than
63% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 117.58 vs. EW: 46.38 )
EW' s 10-Year Interest Coverage Range
Min: 1.04   Max: 9999.99
Current: 46.38

1.04
9999.99
F-Score: 4
Z-Score: 7.03
M-Score: -3.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.22
EW's Operating margin (%) is ranked higher than
93% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. EW: 22.22 )
EW' s 10-Year Operating margin (%) Range
Min: -29.23   Max: 22.84
Current: 22.22

-29.23
22.84
Net-margin (%) 19.15
EW's Net-margin (%) is ranked higher than
95% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. EW: 19.15 )
EW' s 10-Year Net-margin (%) Range
Min: -33.83   Max: 19.15
Current: 19.15

-33.83
19.15
ROE (%) 25.12
EW's ROE (%) is ranked higher than
98% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. EW: 25.12 )
EW' s 10-Year ROE (%) Range
Min: -61.82   Max: 25.12
Current: 25.12

-61.82
25.12
ROA (%) 14.38
EW's ROA (%) is ranked higher than
97% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. EW: 14.38 )
EW' s 10-Year ROA (%) Range
Min: -24.57   Max: 14.38
Current: 14.38

-24.57
14.38
ROC (Joel Greenblatt) (%) 52.55
EW's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. EW: 52.55 )
EW' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -84.23   Max: 58.42
Current: 52.55

-84.23
58.42
Revenue Growth (%) 14.00
EW's Revenue Growth (%) is ranked higher than
89% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. EW: 14.00 )
EW' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 14
Current: 14

0
14
EBITDA Growth (%) 24.00
EW's EBITDA Growth (%) is ranked higher than
94% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. EW: 24.00 )
EW' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 28
Current: 24

0
28
EPS Growth (%) 23.40
EW's EPS Growth (%) is ranked higher than
89% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. EW: 23.40 )
EW' s 10-Year EPS Growth (%) Range
Min: 0   Max: 348.1
Current: 23.4

0
348.1
» EW's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

EW Guru Trades in Q2 2013

Vanguard Health Care Fund 1,311,100 sh (New)
Steven Cohen 156,818 sh (+5716.69%)
Joel Greenblatt 42,122 sh (+526.16%)
Ron Baron 1,985,766 sh (+135.69%)
Meridian Funds 506,700 sh (+33.69%)
PRIMECAP Management 280,000 sh (unchged)
Paul Tudor Jones Sold Out
Jeremy Grantham 56,100 sh (-36.3%)
Jim Simons 245,300 sh (-38.46%)
» More
Q3 2013

EW Guru Trades in Q3 2013

Paul Tudor Jones 5,300 sh (New)
Ray Dalio 25,695 sh (New)
Steven Cohen 506,907 sh (+223.25%)
Jeremy Grantham 72,300 sh (+28.88%)
Jim Simons 281,900 sh (+14.92%)
Ron Baron 2,180,836 sh (+9.82%)
Vanguard Health Care Fund 1,311,100 sh (unchged)
Steven Cohen 250,000 sh (unchged)
PRIMECAP Management 280,000 sh (unchged)
Joel Greenblatt 31,091 sh (-26.19%)
» More
Q4 2013

EW Guru Trades in Q4 2013

Pioneer Investments 179,470 sh (New)
Vanguard Health Care Fund 5,324,000 sh (+306.07%)
Joel Greenblatt 117,760 sh (+278.76%)
PRIMECAP Management 280,000 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Jeremy Grantham 67,987 sh (-5.97%)
Ron Baron 1,533,972 sh (-29.66%)
Jim Simons 188,800 sh (-33.03%)
Steven Cohen 3,398 sh (-99.33%)
» More
Q1 2014

EW Guru Trades in Q1 2014

Paul Tudor Jones 101,400 sh (New)
Steven Cohen 13,278 sh (+290.76%)
Pioneer Investments 256,068 sh (+42.68%)
Vanguard Health Care Fund 5,324,000 sh (unchged)
PRIMECAP Management 280,000 sh (unchged)
Steven Cohen 150,000 sh (unchged)
Jim Simons Sold Out
Ron Baron 1,354,511 sh (-11.7%)
Jeremy Grantham 53,446 sh (-21.39%)
Joel Greenblatt 71,689 sh (-39.12%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-03-31 Reduce -39.12%0.07%$64.17 - $73.93 $ 85.3224%71689
Vanguard Health Care Fund 2013-12-31 Add 306.07%0.83%$61.44 - $78.14 $ 85.3226%5324000
Ron Baron 2013-12-31 Reduce -29.66%0.21%$61.44 - $78.14 $ 85.3226%1533972
Joel Greenblatt 2013-12-31 Add 278.76%0.13%$61.44 - $78.14 $ 85.3226%117760
Ray Dalio 2013-12-31 Sold Out 0.02%$61.44 - $78.14 $ 85.3226%0
Joel Greenblatt 2013-09-30 Reduce -26.19%0.03%$65.25 - $73.4 $ 85.3222%31091
Ray Dalio 2013-09-30 New Buy0.02%$65.25 - $73.4 $ 85.3222%25695
Ron Baron 2013-06-30 Add 135.69%0.4%$62.54 - $84.93 $ 85.3220%1985766
Meridian Funds 2013-06-30 Add 33.69%0.33%$62.54 - $84.93 $ 85.3220%506700
Vanguard Health Care Fund 2013-06-30 New Buy0.32%$62.54 - $84.93 $ 85.3220%1311100
Joel Greenblatt 2013-06-30 Add 526.16%0.1%$62.54 - $84.93 $ 85.3220%42122
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Edwards Lifesciences Corp

Baron Funds Comments on Edwards Lifesciences Corp. - Aug 07, 2012

From Baron Funds Second-Quarter Newsletter:

Of the 101 positions in the Fund, 36 have been held for over five years, which represents 51% of the portfolio. An example of a company we have held for over five years is Edwards Lifesciences Corp. (EW), which was only about 1% of the portfolio as of May 31, 2012, although it was higher previously. Ron has been selling the position since its market cap is now over $10 billion. When the Fund first purchased the stock, the company's market value was $1.5 billion. We think this is a great example of a long-term investment. Edwards Lifesciences is the global leader in the science of heart valves and in the growing market for surgical heart valves. The investment has returned over 230% in the past five years, 505% since our initial purchase in 2003, and 22% on an annualized basis, through May 31, 2012.
Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 31.20
EW's P/E(ttm) is ranked higher than
82% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 67.30 vs. EW: 31.20 )
EW' s 10-Year P/E(ttm) Range
Min: 16.9   Max: 3625
Current: 31.2

16.9
3625
P/B 6.80
EW's P/B is ranked higher than
54% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. EW: 6.80 )
EW' s 10-Year P/B Range
Min: 2.76   Max: 8.46
Current: 6.8

2.76
8.46
P/S 4.61
EW's P/S is ranked higher than
62% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. EW: 4.61 )
EW' s 10-Year P/S Range
Min: 1.97   Max: 7.38
Current: 4.61

1.97
7.38
PFCF 22.50
EW's PFCF is ranked higher than
90% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 2429.50 vs. EW: 22.50 )
EW' s 10-Year PFCF Range
Min: 11.01   Max: 534.25
Current: 22.5

11.01
534.25
EV-to-EBIT 20.43
EW's EV-to-EBIT is ranked higher than
83% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. EW: 20.43 )
EW' s 10-Year EV-to-EBIT Range
Min: 12.1   Max: 69.5
Current: 20.43

12.1
69.5
PEG 2.10
EW's PEG is ranked higher than
92% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 2.10 )
EW' s 10-Year PEG Range
Min: 0.87   Max: 3.5
Current: 2.1

0.87
3.5
Shiller P/E 37.00
EW's Shiller P/E is ranked higher than
89% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 37.00 )
EW' s 10-Year Shiller P/E Range
Min: 27.93   Max: 68.85
Current: 37

27.93
68.85
Current Ratio 4.50
EW's Current Ratio is ranked higher than
82% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. EW: 4.50 )
EW' s 10-Year Current Ratio Range
Min: 0.89   Max: 4.99
Current: 4.5

0.89
4.99
Quick Ratio 3.64
EW's Quick Ratio is ranked higher than
83% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. EW: 3.64 )
EW' s 10-Year Quick Ratio Range
Min: 0.49   Max: 4.1
Current: 3.64

0.49
4.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.90
EW's Price/Tangible Book is ranked higher than
60% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 6.18 vs. EW: 9.90 )
EW' s 10-Year Price/Tangible Book Range
Min: 5.57   Max: 188.29
Current: 9.9

5.57
188.29
Price/DCF (Projected) 2.20
EW's Price/DCF (Projected) is ranked higher than
88% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 2.20 )
EW' s 10-Year Price/DCF (Projected) Range
Min: 1.35   Max: 3.62
Current: 2.2

1.35
3.62
Price/Median PS Value 1.50
EW's Price/Median PS Value is ranked higher than
61% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. EW: 1.50 )
EW' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 2.28
Current: 1.5

0.41
2.28
Price/Peter Lynch Fair Value 2.10
EW's Price/Peter Lynch Fair Value is ranked higher than
95% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 2.10 )
EW' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.94   Max: 3.89
Current: 2.1

0.94
3.89
Price/Graham Number 3.60
EW's Price/Graham Number is ranked higher than
77% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 8.75 vs. EW: 3.60 )
EW' s 10-Year Price/Graham Number Range
Min: 2.08   Max: 33.82
Current: 3.6

2.08
33.82
Earnings Yield (Greenblatt) 4.90
EW's Earnings Yield (Greenblatt) is ranked higher than
71% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. EW: 4.90 )
EW' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 8.3
Current: 4.9

1.4
8.3
Forward Rate of Return (Yacktman) 16.33
EW's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. EW: 16.33 )
EW' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 28.3
Current: 16.33

3.1
28.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EWL.Germany
Edwards Lifesciences Corporation was incorporated in Delaware on September 10, 1999. It is a provider of products and technologies designed to treat advanced cardiovascular disease. The Company is focused specifically on technologies that treat structural heart disease and critically ill patients. Cardiovascular disease is the number-one cause of death in the world, and is the top disease in terms of health care spending in nearly every country. Cardiovascular disease is progressive in that it tends to worsen over time and often affects an individual's entire circulatory system. In its later stages, cardiovascular disease is frequently treated by surgical interventions. The products and technologies provided by the Company to treat advanced cardiovascular disease are categorized into four main areas: Heart Valve Therapy; Critical Care; Cardiac Surgery Systems; and Vascular. The Company's Heart Valve Therapy portfolio is comprised of tissue heart valves and heart valve repair products. Tissue heart valves and repair products are used to replace or repair a patient's diseased or defective heart valve. In the Critical Care area, the Company is a provider of hemodynamic monitoring equipment used to measure a patient's cardiovascular function and in disposable pressure transducers, and also provides central venous access products for fluid and drug delivery. The Company's Cardiac Surgery Systems portfolio comprises a diverse line of products for use during cardiac surgery including cannula, EMBOL-X technologies, and other disposable products used during cardiopulmonary bypass procedures. In December 2007, the Company acquired the CardioVations line of products used in MIS. The Company's Vascular portfolio includes a line of balloon catheter-based products, surgical clips and inserts, artificial implantable grafts, and stents for which approval is being sought for use in treatment of peripheral vascular disease. It operates manufacturing facilities in a number of geographies around the world. It maintains heart valve manufacturing facilities in California, Switzerland, and Singapore. Critical Care products are manufactured mainly in the Company's facilities located in Puerto Rico and the Dominican Republic. Edwards' Cardiac Surgery Systems and Vascular products are manufactured mainly in Utah and Puerto Rico, respectively. The Company sold the LifeStent product line in January 2008, but would continue to manufacture these products for the buyer until the earlier of mid-2010 or the transfer of manufacturing to the buyer. The healthcare marketplace continues to be competitive with strong global and local competitors. The Company competes with many companies, ranging from small start-up enterprises to companies that are larger and more established than it with access to financial resources. Furthermore, rapid product development and technological change characterize the market in which the Company competes. The Company's primary competito
» More Articles for EW

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: EW, NUAN, MNK, CROX, IRDM Nov 03 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
Ron Baron's Favorite Stocks Jun 28 2013 
Ron Baron's Market Strategy - CNBC Interview Jun 28 2013 
Guru Stocks at 52-Week Lows: EC, OKS, LFL, LINE, EW May 06 2013 
Insider Buys at 52-Week Lows May 04 2013 
Medical Technology Industry Reports Insider Sells at 52-Week Lows Apr 25 2013 
Baron Funds Comments on Edwards Lifesciences Corp. Aug 07 2012 
Weekly CFO Sells Highlight: OMC, NEE, EW, STZ, GRPN Aug 08 2012 
WEEKLY CFO SELLS HIGHLIGHT: OMC, NEE, EW, STZ, GRPN Aug 06 2012 

More From Other Websites
Edwards Lifesciences To Host Earnings Conference Call on July 29, 2014 Jul 15 2014
3 Stocks Pushing The Health Services Industry Downward Jul 14 2014
Study Explores Expanded Use For Edwards' And Medtronic's New Heart Valves Jul 08 2014
Edwards Lifesciences Monitor Gets FDA Nod Jul 02 2014
Edwards Receives FDA Clearance For Advanced Noninvasive Monitoring System Jun 30 2014
Edwards Lifesciences' Sapien XT Gains Approval, Competition Rife Jun 26 2014
Company News for June 18, 2014 Jun 18 2014
Edwards Lifesciences' Aortic Heart Valve Gets FDA Approval Jun 17 2014
Edwards shares rise on new heart valve approval Jun 17 2014
Edwards shares rise on new heart valve approval Jun 17 2014
Edwards Lifesciences Rises After Sapien XT Approval Jun 17 2014
Edwards shares jump after company wins approval for new heart valve Jun 17 2014
Stocks to Watch: Edwards Lifesciences, Amira, Forest Oil Jun 17 2014
Stock Futures Aim Firmly Lower; Amira Natural, Edwards Jump Jun 17 2014
FDA Approves Second Generation Heart Valve From Edwards Lifesciences Jun 16 2014
Edwards wins U.S. nod for next generation Sapien XT heart valve system Jun 16 2014
Edwards Lifesciences receives FDA approval for SAPIEN XT valve Jun 16 2014
Edwards Lifesciences Launching SAPIEN XT Valve In The U.S. Jun 16 2014
Covidian acquisiton may signal increased sector M&A, says CRT Capital Jun 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide